Cold kits with Tc-99m labelling for diagnosis

Tc-IK-7

V09CA02

OGYI-T9245/01

Technetium (^99mTc) succimer injection

Dimercaptosuccinic acid

1.5 mg

• Stannous chloride dihydrate
• Ascorbic acid
• Calcium gluconate

• Kidney scintigraphy, static kidney imaging, localisation of the kidneys with imaging
• Determination of the functional mass of the kidney
• Determination of the relative function ratio (percentage) of the left and right kidneys

1.0–1.8 GBq

6 injection vials

See in the Summary of Product Charasteristics

24 months after radiolabelling: 8 h

2-8°C after radiolabelling: ≤ 25°C

Tc-IK-8

V09CA01

OGYI-T-9244/01

Technetium (^99mTc) pentate injection

Diethylenetriamino pentaacetic acid

9.0 mg

• Stannous chloride dihydrate
• Ascorbic acid
• Sodium chloride

• Dynamic studies of kidney, determination of kidney perfusion, glomerural filtration rate, total and partial kidney function
• Examination of the cerebral blood circulation
• Examination of the gastrointestinal tract by using labelled foodstuff or drink
• Examination of liquor circulation

0.8–2.4 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months after radiolabelling: 8 h

 ≤ 25°C after radiolabelling: ≤ 25°C

Tc-IK-25

V09CA

OGYI-T-9141/01

Technetium (^99mTc) EC injection

Ethylene-dicysteine

2.0 mg

Vial A

• Disodium hydrogen phosphate dihydrate
• Mannitol
• Ascorbic acid
• Sodium edetate

Vial B

• Stannous chloride dihydrate
• Ascorbic acid
• Tartaric acid

Vial C

• Potassium dihydrogen phosphate
• Ascorbic acid

• Dynamic studies of kidney for renal tubular function

0.8–1.6 GBq

3 x 4 injection vials

See in the Summary of Product Charasteristics

12 months after radiolabelling: 8 h

2-8°C after radiolabelling: ≤ 25°C

Tc-IK-5

V09BA03

OGYI-T9246/01

Technetium (^99mTc) tin pyrophosphate injection

Sodium pyrophosphate

25.0 mg

• Stannous chloride dihydrate
• Sodium chloride

• Bone and acute myocardial infarct scintigraphy
• Blood pool scintigraphy
• Spleen scintigraphy

1.3–3.0 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months after radiolabelling: 3 h

≤ 25°C after radiolabelling: ≤ 25°C

Tc-IK-10

V09BA02

OGYI-T9702/01

Technetium (^99mTc) medronate injection

Medronic acid

5.0 mg

• Stannous chloride dihydrate
• Ascorbic acid
• Urea

For bone scintigraphy (diagnostic skeletal imaging) Use of the preparation is highly recommended for:

• Primer bone tumours
• Metastases of other tumours, for example prostate/breast/lung cancer
• Osteomyelitis
• Metabolic bone diseases
• Paget’s disease

3.0–6.0 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months after radiolabelling: 6 h

2-8°C after radiolabelling: ≤ 25°C

Tc-IK-81

V09GA01

OGYI-T-23814/01

Technetium (^99mTc) sestamibi injection

[tetrakis (1-isocyanide-2-methoxy-2-methylpropyl-)copper(I)] tetrafluoroborate

1.0 mg

• Cysteine hydrochloride monohydrate
• Sodium citrate
• Stannous chloride dihydrate
• D-Mannitol

• Myocardial perfusion scintigraphy for the detection and localisation of coronary artery disease (angina pectoris and myocardial infarction)
• Assessment of global ventricular function.First-pass technique for determination of ejection fraction and/or ECG-triggered, gated SPECT for evaluation of left ventricular ejection fraction, volumes and regional wall motion
• Scintimammography for the detection of suspected breast cancer when mammography is equivocal, inadequate or indeterminate
• Localisation of hyperfunctioning parathyroid tissue in patients with recurrent or persistent disease in both primary and secondary hyperparathyroidism, and in patients with primary hyperparathyroidism scheduled to undergo initial surgery of the parathyroid glands.

max. 15.0 GBq

6 injection vials

See in the Summary of Product Charasteristics

24 months after radiolabelling: 16 h

2-8°C after radiolabelling: ≤ 25°C

Tc-IK-2

V09DB07

OGYI-T9288/01

Technetium (^99mTc) phytate injection

Sodium phytate

15.0 mg

• Stannous chloride dihydrate
• Sodium chloride

• Morphological examination of the liver by imaging technique
• Diagnosis of benign and malignant liver tumours and monitoring of the therapy
• Dynamic examination of flow disorders in the hepatobiliary system (blockage in the biliary duct, etc.)

0.8–1.6 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months after radiolabelling: 3 h

≤ 25°C after radiolabelling: ≤ 25°C

Tc-IK-6

V09DA02

OGYI-T-9210/01

Technetium (^99mTc) etifenin injection

Diethyl-acetanilid-imino diacetic acid

30.0 mg

• Stannous chloride dihydrate
• Ascorbic acid

• Dynamic examination of the function of the hepatocytes
• Liver transplant evaluation
• Dynamic examination of flow disorders in the hepatobiliary system (blockage in the biliary duct, etc.)
• Examination of the acute cholecystitis
• Diagnosis of focalis nodular hyperplasia

0.8–1.6 GBq

6 injection vials

See in the Summary of Product Charasteristics

24 months after radiolabelling: 6 h

2-8°C after radiolabelling: 2-8°C